<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01530919</url>
  </required_header>
  <id_info>
    <org_study_id>291.97</org_study_id>
    <nct_id>NCT01530919</nct_id>
  </id_info>
  <brief_title>Minimally Invasive Radioguided Parathyroidectomy</brief_title>
  <acronym>MIRP</acronym>
  <official_title>Minimally Invasive Radioguided Parathyroidectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norton Healthcare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jewish Hospital and St. Mary's Healthcare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this research study is to evaluate the effectiveness of a minimally
      invasive surgical approach to removing parathyroid gland(s). The researchers are also
      interested in analyzing abnormal parathyroid tissue for changes in genes and proteins that
      may contribute to overactive parathyroid gland(s).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific aims of this study are to determine the safety and efficacy of minimally
      invasive radioguided parathyroidectomy, to determine the positive and negative predictive
      value of sestamibi scanning to detect parathyroid adenomas, and to differentiate adenomas
      from parathyroid hyperplasia. In addition, this study aims to determine the value of
      intraoperative parathyroid hormone assay to verify biochemical cure of primary
      hyperparathyroidism, to determine whether minimally invasive radioguided parathyroidectomy is
      cos-effective, and to collect abnormal parathyroid tissue at the time of surgery for tissue
      analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1998</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The positive and negative predictive value of sestamibi scanning to detect parathyroid adenomas.</measure>
    <time_frame>2-3days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The value of intraoperative parathyroid hormone assay to verify biochemical cure or primary hyperparathyroidism</measure>
    <time_frame>2-3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collection of abnormal parathyroid tissue at the time of surgery for tissue analysis</measure>
    <time_frame>day of surgery (1 day)</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">856</enrollment>
  <condition>Primary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>Parathyroid surgery</arm_group_label>
    <description>Database of patients who have undergone minimally invasive radioguided parathyroidectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Minimally invasive radioguided parathyroidectomy</intervention_name>
    <description>After the patient is prepared for surgery and under local anesthesia, the initial incision by the surgeon will be 2-3 cm. The surgeon will dissect in the designated quadrant until the parathyroid gland is identified.</description>
    <arm_group_label>Parathyroid surgery</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Small portion of abnormal parathyroid gland that is removed during surgery is frozen and
      stored for future research.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults and minors diagnosed with primary hyperparathyroidism that will be having minimally
        invasive radioguided parathyroidectomy surgery to correct this condition at either Norton
        Hospital, University of Louisville Hospital or Jewish Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with biochemical evidence of primary hyperparathyroidism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J Flynn, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Quillo AR, Bumpous JM, Goldstein RE, Fleming MM, Flynn MB. Minimally invasive parathyroid surgery, the Norman 20% rule: is it valid? Am Surg. 2011 Apr;77(4):484-7.</citation>
    <PMID>21679561</PMID>
  </results_reference>
  <results_reference>
    <citation>Grady JA, Bumpous JM, Fleming MM, Flynn MB, Turbiner E, Lentsch EJ, Ziegler CH. Advantages of a targeted approach in minimally invasive radioguided parathyroidectomy surgery for primary hyperparathyroidism. Laryngoscope. 2006 Mar;116(3):431-5.</citation>
    <PMID>16540904</PMID>
  </results_reference>
  <results_reference>
    <citation>Flynn MB, Quayyum M, Goldstein RE, Bumpous JM. Outpatient parathyroid surgery: ten-year experience: is it safe? Am Surg. 2015 May;81(5):472-7.</citation>
    <PMID>25975331</PMID>
  </results_reference>
  <results_reference>
    <citation>Flynn MB, Bumpous JM, Schill K, McMasters KM. Minimally invasive radioguided parathyroidectomy. J Am Coll Surg. 2000 Jul;191(1):24-31.</citation>
    <PMID>10898180</PMID>
  </results_reference>
  <results_reference>
    <citation>Hutchinson JR, Yandell DW, Bumpous JM, Fleming MM, Flynn MB. Three-year financial analysis of minimally invasive radio-guided parathyroidectomy. Am Surg. 2004 Dec;70(12):1112-5.</citation>
    <PMID>15663056</PMID>
  </results_reference>
  <results_reference>
    <citation>Goldstein RE, Carter WM 2nd, Fleming M, Bumpous J, Lentsch E, Rice M, Flynn M. Unilateral cervical surgical exploration aided by intraoperative parathyroid hormone monitoring in patients with primary hyperparathyroidism and equivocal sestamibi scan results. Arch Surg. 2006 Jun;141(6):552-7; discussion 557-9.</citation>
    <PMID>16785355</PMID>
  </results_reference>
  <results_reference>
    <citation>Kartha SS, Chacko CE, Bumpous JM, Fleming M, Lentsch EJ, Flynn MB. Toxic metabolic encephalopathy after parathyroidectomy with methylene blue localization. Otolaryngol Head Neck Surg. 2006 Nov;135(5):765-8.</citation>
    <PMID>17071309</PMID>
  </results_reference>
  <results_reference>
    <citation>Conn CA, Clark J, Bumpous J, Goldstein R, Fleming M, Flynn MB. Hypocalcemia after neck exploration for untreated primary hyperparathyroidism. Am Surg. 2006 Dec;72(12):1234-7.</citation>
    <PMID>17216827</PMID>
  </results_reference>
  <results_reference>
    <citation>Han N, Bumpous JM, Goldstein RE, Fleming MM, Flynn MB. Intra-operative parathyroid identification using methylene blue in parathyroid surgery. Am Surg. 2007 Aug;73(8):820-3.</citation>
    <PMID>17879694</PMID>
  </results_reference>
  <results_reference>
    <citation>Stephen ET, Quillo AR, Lewis KE, Harden FL, Bumpous JM, Flynn MB, Callender GG. Operative failure rate and documentation of family history in young patients undergoing focused parathyroidectomy for primary hyperparathyroidism. Am Surg. 2015 Jun;81(6):585-90.</citation>
    <PMID>26031271</PMID>
  </results_reference>
  <results_reference>
    <citation>Bumpous JM, Goldstein RL, Flynn MB. Surgical and calcium outcomes in 427 patients treated prospectively in an image-guided and intraoperative PTH (IOPTH) supplemented protocol for primary hyperparathyroidism: outcomes and opportunities. Laryngoscope. 2009 Feb;119(2):300-6. doi: 10.1002/lary.20049.</citation>
    <PMID>19160424</PMID>
  </results_reference>
  <results_reference>
    <citation>Young VN, Osborne KM, Fleming MM, Flynn MB, Goldstein RE, Bumpous JM. Parathyroidectomy in the elderly population: does age really matter? Laryngoscope. 2010 Feb;120(2):247-52. doi: 10.1002/lary.20706.</citation>
    <PMID>19950385</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2011</study_first_submitted>
  <study_first_submitted_qc>February 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2012</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Michael B. Flynn, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

